News

Evaxion has delivered a 2025 reset built on external validation and extended runway. The techbio vaccine developer reported full-year...

Aquestive Therapeutics will resubmit the U.S. NDA for Anaphylm, its sublingual epinephrine film for severe allergic reactions, in the...

ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy, its FDA- and EC-approved intranasal epinephrine, in...

Santhera has appointed Marc Clausse as Chief Commercial Officer, effective June 1, 2026, succeeding Geert Jan van Daal, who...

Enzon Pharmaceuticals has extended the deadline for its exchange offer to convert Series C non-convertible redeemable preferred stock into...

TG Therapeutics will showcase new BRIUMVI (ublituximab-xiiy) data at AAN 2026 in Chicago, including the first Phase 4 real-world...

Ataibeckley has cleared a key regulatory hurdle for its lead program in treatment-resistant depression, securing FDA alignment at end-of-Phase...

Atea Pharmaceuticals has completed enrollment of its North American phase 3 C-BEYOND trial evaluating the fixed-dose combination of bemnifosbuvir...

Metagenomi Therapeutics (Nasdaq: MGX) reported full-year 2025 results, unveiled a corporate rebrand, and detailed clinical readiness steps for its...

Camp4 Therapeutics reported full-year 2025 results, advanced its lead SYNGAP1 program toward first-in-human testing, secured a discovery-stage collaboration with...